<unk>  is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.
Tepotinib
Icotinib
Crizotinib
Afatinib
Nilotinib
Imatinib
Neratinib
Tucatinib